Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
07/1999
07/06/1999US5919438 Combinatory immixture of (a) at least one antifungal agent and (b) at least one halogenated antibacterial agent other than a macrolide or pyranoside
07/06/1999US5919400 Organic mercaptan, sulfide or disulfide stabilizer
07/06/1999CA2182521C Method for reproducing in vitro the proteolytic activity of the ns3 protease of hepatitis c virus (hcv)
07/06/1999CA2177146C Heterocyclic benzenesulfonylimine derivatives as inhibitors of il-1 action
07/06/1999CA1340638C Cephalosporin derivatives
07/06/1999CA1340627C T4 glycoprotien fragments and use of fragments of t4 in the treatment of aids
07/01/1999WO1999032648A1 Recombinant rhabdovirus containing a heterologous fusion protein
07/01/1999WO1999032645A1 Humanized monoclonal antibodies that protect against shiga toxin induced disease
07/01/1999WO1999032635A1 Acetyl-coa-carboxylase from candida albicans
07/01/1999WO1999032634A2 Compositions derived from mycobacterium vaccae and methods for their use
07/01/1999WO1999032516A2 Pharmaceutical compositions containing the long pentraxin ptx3
07/01/1999WO1999032498A1 Antibiotic tkr2999, process for the preparation thereof and microbe
07/01/1999WO1999032497A1 Phosphonocephem derivatives, process for the preparation of the same, and use thereof
07/01/1999WO1999032451A1 Azepine or larger medium ring derivatives and their use as pharmaceuticals
07/01/1999WO1999032450A1 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
07/01/1999WO1999032448A1 Substituted pyridine and pyridazine compounds and their pharmaceutical use
07/01/1999WO1999032146A1 Intranasal yellow fever vaccination
07/01/1999WO1999032141A1 Ifnar2/ifn complex
07/01/1999WO1999032138A1 Method for reducing susceptibility to hiv infection
07/01/1999WO1999032133A1 Methods and compositions for the treatment and prevention of staphylococcus aureus infections
07/01/1999WO1999032128A1 Orally administrable solid ribavirin dosage forms and process for making them
07/01/1999WO1999032121A1 Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
07/01/1999WO1999032113A1 Application of enzyme prodrugs as anti-infective agents
07/01/1999WO1999032111A1 INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
07/01/1999WO1999015186A8 Cationic polymers as toxin-binding agents
07/01/1999CA2315720A1 Inhibition of p38 kinase activity using substituted heterocyclic ureas
07/01/1999CA2315539A1 Compositions derived from mycobacterium vaccae and methods for their use
07/01/1999CA2315201A1 Application of enzyme prodrugs as anti-infective agents
07/01/1999CA2314980A1 Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses
07/01/1999CA2313805A1 Method for reducing susceptibility to hiv infection
07/01/1999CA2309882A1 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
06/1999
06/30/1999EP0925789A1 Topical azithromycin compositions for the treatment of ocular infections
06/30/1999EP0925309A1 Use of proteins as anti-retroviral agents
06/30/1999EP0925308A2 Compositions and methods for treating infections using analogues of indolicidin
06/30/1999EP0925307A1 Enzyme and dna sequence encoding same
06/30/1999EP0925298A1 Substituted 6,6-hetero-bicyclic derivatives
06/30/1999EP0925287A1 Heterocyclic metalloprotease inhibitors
06/30/1999EP0925284A1 New polycyclic phthalazin derivatives and their use
06/30/1999EP0925073A1 $i(STAPHYLOCOCCUS AUREUS) ANTIGEN
06/30/1999EP0925071A1 Muc-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
06/30/1999EP0925070A1 Antifungal combination therapy
06/30/1999EP0925065A1 Water miscible erythromycin solutions
06/30/1999EP0925059A1 Protein-lipid vesicles and autogenous vaccine comprising the same
06/30/1999CN1221452A Hybrid interferon compositions and method of use
06/30/1999CN1221421A Novel water-soluble c-ring analogues of 20(S)-camptothecin
06/30/1999CN1221420A Novel water-soluble analogues of 20(S)-camptothecin
06/30/1999CN1221349A Cellular vaccines immunotherapeutics and methods for their preparation
06/30/1999CN1221347A Medicament for optimising mucosal viscosity and stimulating intestinal function
06/30/1999CN1221344A Extractable compounds and method for making and using the same
06/30/1999CA2256002A1 7-bromo- and 7,7-dibromo-cepham and cephem derivatives
06/29/1999US5917017 Diphtheria toxin vaccines bearing a mutated R domain
06/29/1999US5916906 Compositions comprising nicotinylalanine and an inhibitor of glycine conjugation or vitamin B6
06/29/1999US5916893 Treatment of a latent infection of herpes virus
06/29/1999US5916887 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators
06/29/1999US5916878 Dipeptide of either gamma-glutamyl-l-tryptophan or beta-aspartyl-l-tryptophan; administering to the patients to reduce the risks infections from microorganism
06/29/1999US5916873 Bactericides; grampositive bacteria
06/29/1999US5916872 Efficiency; long half-life
06/29/1999US5916806 There is also provided a vaccine effective against hiv.
06/29/1999US5916803 Target cell-specific non-viral vectors for inserting genes into cells, pharmaceutical compositions comprising such vectors and their use
06/29/1999US5916754 Detecting infection
06/29/1999US5916581 Iodine antimicrobial compositions containing nonionic surfactants and halogen anions
06/29/1999US5916570 Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
06/29/1999US5916563 Parvovirus protein presenting capsids
06/29/1999US5916562 A conjugate molecule, consisting of a synthetic peptide having amino acid sequence with is either n-terminal amino acid residues 1 to 14 or c-terminal 314 to 341 of p2 outer membrane protein of strain of haemophilus influenza type b
06/29/1999CA2016584C Anthracycline conjugates having a novel linker and methods for their production
06/29/1999CA1340617C Expression of hepatitis b s and pres2 protiens in methylotrophic yeasts
06/29/1999CA1340612C Cell specific cytotoxic agents derived from diphtheria toxin
06/26/1999CA2256060A1 Triazole derivative or salt thereof, preparation process thereof and pharmaceutical containing said compound as an effective ingredient
06/24/1999WO1999031280A1 Screening assays for the detection and diagnosis of influenza virus
06/24/1999WO1999031267A1 Methods for the simultaneous identification of novel biological targets and lead structures for drug development
06/24/1999WO1999031262A2 Needle-free injection of formulated nucleic acid molecules
06/24/1999WO1999031257A2 Protein expression in baculovirus vector expression systems
06/24/1999WO1999031250A2 Constitutive expression of non-infectious hiv-like particles
06/24/1999WO1999031246A1 Compounds and methods for the detection and prevention of t. cruzi infection
06/24/1999WO1999031132A1 NOVEL SURFACE PROTEIN OF $i(NEISSERIA MENINGITIDIS)
06/24/1999WO1999031127A1 Cyclopeptolides
06/24/1999WO1999031122A1 Antipicornaviral compounds and methods for their use and preparation
06/24/1999WO1999031110A1 Cephalosporin antibiotics
06/24/1999WO1999031105A1 3-substituted adenines via2-thioxanthines
06/24/1999WO1999031104A1 Preparation of 3-substituted adenines and imidazo pyridines
06/24/1999WO1999031103A1 Preparation of 3-substituted adenines
06/24/1999WO1999031102A1 Purine derivatives having phosphodiesterase iv inhibition activity
06/24/1999WO1999031099A1 Integrin receptor antagonists
06/24/1999WO1999031061A1 Integrin receptor antagonists
06/24/1999WO1999031047A1 Cyclohexene carboxylates as neuraminidase inhibitors
06/24/1999WO1999030742A1 Therapeutic use of lentiviral vectors
06/24/1999WO1999030738A2 Diagnostics and therapeutics for transmissible spongiform encephalopathy and methods for the manufacture of non-infective blood products and tissue derived products
06/24/1999WO1999030737A1 Use of microparticles combined with submicron oil-in-water emulsions
06/24/1999WO1999030735A1 UGC (UPSTREAM GENE OF cdsA)
06/24/1999WO1999030728A1 Pharmaceutical compositions based on dalforpristin and quinupristin and preparation
06/24/1999WO1999030720A1 Method for inhibiting cyclooxygenase-2 and tumor necrosis factor alpha
06/24/1999WO1999030713A1 Integrin receptor antagonists
06/24/1999WO1999030712A1 Agents
06/24/1999WO1999030710A1 USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
06/24/1999WO1999030709A1 Integrin receptor antagonists
06/24/1999WO1999030699A1 Modulators of cysteine protease
06/24/1999WO1999030693A2 A double capsule for the administration of active principles in multiple therapies
06/24/1999WO1999030670A2 Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
06/24/1999WO1999015692A3 Dengue virus antigens and treatment of dengue fever
06/24/1999WO1999007728A3 Linear peptides derived from antibiotic peptides, preparation and use for vectoring active substances
1 ... 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 ... 1798